# US 2004/0082007 A1 · 47174, a novel human glycosyltransferase and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082007 A1
- Document ID: US20040082007A1
- Status: Published application
- Kind: A1
- Application number: 10/713,345
- Filed: 2003-11-14
- Published: 2004-04-29
- Earliest claimed: 2000-10-06
- Assignees: Millennium Pharmaceuticals, Inc.
- Inventors: Rosana Kapeller-Libermann
- Web page: https://patentgrep.com/patent/US20040082007A1

## CPC

- C12N 9/1048: {Glycosyltransferases (2.4)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides isolated nucleic acids molecules, designated 47174 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47174 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47174 gene has been introduced or disrupted. The invention still further provides isolated 47174 proteins, fusion proteins, antigenic peptides and anti-47174 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. The invention also provides methods of modulating pain or pain related disorders utilizing the compositions of the invention. Accordingly, methods of treating, preventing and/or diagnosing neurological disorders are disclosed.

## Claims

### Claim 1

An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3; and
b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

### Claim 4 (depends on 1)

A host cell that contains the nucleic acid molecule of claim 1.

### Claim 5

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.

### Claim 6 (depends on 5)

The polypeptide of claim 5 further comprising heterologous amino acid sequences.

### Claim 7 (depends on 5)

An antibody, or antigen binding fragment thereof, that selectively binds to a polypeptide of claim 5.

### Claim 8 (depends on 4)

A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:2, the method comprising culturing the host cell of claim 4 under conditions in which the nucleic acid molecule is expressed.

### Claim 9 (depends on 5, 8)

A method for detecting the presence of a polypeptide of claim 5 in a sample, comprising:
a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and
b) determining whether the compound binds to the polypeptide in the sample.

### Claim 10 (depends on 9)

The method of claim 9, wherein the compound that binds to the polypeptide is an antibody.

### Claim 11 (depends on 5)

A kit comprising a compound that selectively binds to a polypeptide of claim 5 and instructions for use.

### Claim 12 (depends on 1)

A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

### Claim 14 (depends on 1)

A kit comprising a compound that selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

### Claim 15 (depends on 5)

A method for identifying a compound which binds to a polypeptide of claim 5 comprising the steps of:
a) contacting a polypeptide, or a cell expressing a polypeptide of claim 5 with a test compound; and
b) determining whether the polypeptide binds to the test compound.

### Claim 16 (depends on 5)

A method for modulating the activity of a polypeptide of claim 5, comprising contacting a polypeptide or a cell expressing a polypeptide of claim 5 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

### Claim 17 (depends on 5)

A method of inhibiting aberrant activity of a 47174-expressing cell, comprising contacting a 47174-expressing cell with a compound that modulates the activity or expression of a polypeptide of claim 5, in an amount which is effective to reduce or inhibit the aberrant activity of the cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is selected from the group consisting of a peptide, a phosphopeptide, a small organic molecule, and an antibody.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cell is a neural or a glial cell.

### Claim 20 (depends on 1)

A method of treating or preventing a disorder characterized by aberrant activity of a 47174-expressing cell, in a subject, comprising:
administering to the subject an effective amount of a compound that modulates the activity or expression of a nucleic acid molecule of claim 1, such that the aberrant activity of the 47174-expressing cell is reduced or inhibited.
